ID   SJSA-1
AC   CVCL_1697
SY   SJSA1; SJSA; OsA-CL; OSA-CL; OsACL; OSACL; Os-A; OSA; OsA
DR   BTO; BTO_0004216
DR   CLO; CLO_0009031
DR   EFO; EFO_0002330
DR   AddexBio; C0004004/64
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2098
DR   BioGRID_ORCS_Cell_line; 468
DR   BioSample; SAMN03472540
DR   BioSample; SAMN10987778
DR   cancercelllines; CVCL_1697
DR   CCTCC; GDC0257
DR   Cell_Model_Passport; SIDM01112
DR   ChEMBL-Cells; CHEMBL3308885
DR   ChEMBL-Targets; CHEMBL2366298
DR   CLS; 305096
DR   Cosmic; 687931
DR   Cosmic; 909717
DR   Cosmic; 931911
DR   Cosmic; 1070843
DR   Cosmic; 1074396
DR   Cosmic; 1097756
DR   Cosmic; 1188476
DR   Cosmic; 1529912
DR   Cosmic-CLP; 909717
DR   DepMap; ACH-000748
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS327EZG
DR   ENCODE; ENCBS489PLT
DR   GDSC; 909717
DR   GEO; GSM320826
DR   GEO; GSM879221
DR   GEO; GSM887574
DR   GEO; GSM888657
DR   GEO; GSM1670426
DR   GEO; GSM1676316
DR   GEO; GSM1701650
DR   IARC_TP53; 27705
DR   IGRhCellID; SJSA1
DR   LiGeA; CCLE_243
DR   LINCS_LDP; LCL-1433
DR   PharmacoDB; SJSA1_1382_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1697
DR   PubChem_Cell_line; CVCL_1697
DR   Wikidata; Q54953586
RX   PubMed=2766305;
RX   PubMed=8275086;
RX   PubMed=12645653;
RX   PubMed=15150091;
RX   PubMed=17354236;
RX   PubMed=19787792;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21519327;
RX   PubMed=22460905;
RX   PubMed=23144859;
RX   PubMed=25984343;
RX   PubMed=26351324;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30214690;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
WW   Provider; Altogen; Xenograft model; https://altogenlabs.com/xenograft-models/sarcoma-xenograft/sjsa1-xenograft-model/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Doubling time: 31 hours (PubMed=25984343); ~24 hours (PubMed=21519327).
CC   HLA typing: A*30:02,74:01; B*07:06,57:03; C*15:05,18:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Heterozygous (Cosmic-CLP=909717; DepMap=ACH-000748).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP=909717; DepMap=ACH-000748).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; CRISPR screening.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Phenotyping; shRNA library screening.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=90.72%; Native American=0%; East Asian, North=1.2%; East Asian, South=0%; South Asian=0%; European, North=2.05%; European, South=6.03% (PubMed=30894373).
CC   Misspelling: SISA; Cosmic=1529912.
CC   Misspelling: SJSA2; Cosmic=1097756.
CC   Derived from site: In situ; Bone, femur; UBERON=UBERON_0000981.
ST   Source(s): ATCC=CRL-2098; Cosmic-CLP=909717; PubMed=19787792
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 12,13
ST   D16S539: 9,10
ST   D18S51: 15,17
ST   D19S433: 14.2,15 (ATCC=CRL-2098)
ST   D19S433: 15 (PubMed=19787792)
ST   D21S11: 28,33.2
ST   D2S1338: 21,25
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 22,23
ST   Penta D: 2.2,10
ST   Penta E: 11,14
ST   SE33: 21.2,27.2
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 19
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 45
//
RX   PubMed=2766305;
RA   Roberts W.M., Douglass E.C., Peiper S.C., Houghton P.J., Look A.T.;
RT   "Amplification of the gli gene in childhood sarcomas.";
RL   Cancer Res. 49:5407-5413(1989).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4;
RA   Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N.,
RA   Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J.,
RA   Poremba C.;
RT   "Chromosomal alterations in osteosarcoma cell lines revealed by
RT   comparative genomic hybridization and multicolor karyotyping.";
RL   Cancer Genet. Cytogenet. 140:145-152(2003).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23144859; DOI=10.1371/journal.pone.0048262; PMCID=PMC3492335;
RA   Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H.,
RA   Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E.,
RA   Myklebost O., Meza-Zepeda L.A.;
RT   "Integrative analysis reveals relationships of genetic and epigenetic
RT   alterations in osteosarcoma.";
RL   PLoS ONE 7:e48262.1-e48262.20(2012).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035.1-140035.12(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476;
RA   Teicher B.A., Polley E.C., Kunkel M.W., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30214690; DOI=10.18632/oncotarget.26029; PMCID=PMC6132345;
RA   Mason-Osann E., Dai A., Floro J., Lock Y.J., Reiss M., Gali H.,
RA   Matschulat A., Labadorf A., Flynn R.L.;
RT   "Identification of a novel gene fusion in ALT positive osteosarcoma.";
RL   Oncotarget 9:32868-32880(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//